Biogen Idec Inc. (BIIB:US), the fourth- largest U.S. biotechnology company by market value, won a U.S. patent that may guard its experimental multiple sclerosis pill from generic competition for eight more years than anticipated.
The patent expiring in 2028 was issued on an application filed in February 2012 by Weston, Massachusetts-based Biogen, according to the U.S. Patent and Trademark Office’s website. The Food and Drug Administration is expected to decide whether to approve the medicine, Tecfidera, by the end of the month.
The drug had been protected by three patents that expire from October 2019 to May 2020, according to Eric Schmidt, a New York-based analyst with Cowen & Co. who estimates Tecfidera could generate $3.2 billion in annual sales in 2017. The drug was tested in doses given twice a day and three times a day, and the patent today covers administration twice daily.
“They have a novel discovery here in that they were first to observe that the lower dose of the drug, maybe somewhat surprisingly, was as active as the high dose,” Schmidt said today in a telephone interview. “The burden of proof will be on anyone else to show this patent isn’t valid.”
The patent office said in December that claims related to the application had been allowed, so today’s issuance was expected, Schmidt said. He has an outperform rating on the comapny’s shares.
Biogen rose (BIIB:US) less than 1 percent to $175.61 at the close in New York. The shares gained 46 percent in the past 12 months.
2.1 Million Patients
Biogen already sells the MS treatments Avonex, given by injection, and Tysabri, administered intravenously. Tecfidera, formerly known as BG-12, would be Biogen’s first pill for MS, a disease that affects more than 2.1 million people globally, according to the National Multiple Sclerosis Society.
“The patent is important because it removes some of the uncertainty about the current patent estate which goes out to 2019/2020 in the U.S.,” Michael Yee, an analyst with RBC Capital Markets, said by telephone. “That’s a relatively short timeframe for big blockbuster drugs.”
Yee said the added protection may be worth as much as $10 a share to $15 a share or more based on a discounted cash flow analysis. He said a maker of generic drugs may still try to challenge the patents.
“The patent for this dosing regimen is recognition of the remarkable innovation Tecfidera represents for the MS community,” Biogen Chief Executive Officer George Scangos said in a statement. “The tremendous research investment required to study and validate the patented dosing regimen is an example of innovation that leads to meaningful benefits to patients.”
To contact the reporters on this story: Meg Tirrell in New York at firstname.lastname@example.org; Susan Decker in Washington at email@example.com
To contact the editors responsible for this story: Elizabeth Wasserman at firstname.lastname@example.org; Reg Gale at email@example.com